Neurocrine Biosciences Reinforces INGREZZA Efficacy with New Tardive Dyskinesia Data
Event summary
- Neurocrine Biosciences presented new post-hoc data from the KINECT 4 trial showing 94% of patients treated with INGREZZA achieved either symptomatic remission or clinically meaningful response (≥30% reduction in AIMS score).
- A separate Medicare claims analysis found 90% of tardive dyskinesia patients had at least one hepatic risk factor, highlighting INGREZZA's unique dosing approval for hepatic impairment.
- The data was presented at the 2026 Psych Congress Elevate, reinforcing INGREZZA's broad clinical impact across a range of patients.
The big picture
Neurocrine Biosciences is strengthening its position in the tardive dyskinesia market with robust clinical data supporting INGREZZA's efficacy across a broad patient population. The company's focus on addressing hepatic risk factors in TD treatment decisions underscores its strategic emphasis on personalized medicine. As the only VMAT2 inhibitor with approved dosing for hepatic impairment, INGREZZA's differentiation could drive long-term market leadership in this underserved neurological disorder.
What we're watching
- Market Differentiation
- Whether INGREZZA's unique hepatic dosing approval will drive further market share gains against competitors in the tardive dyskinesia space.
- Clinical Validation
- The pace at which additional studies replicate these findings, particularly among patients who do not meet the symptomatic remission threshold.
- Regulatory Strategy
- How Neurocrine leverages this data to support potential label expansions or new indications for INGREZZA.